Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

The Advent of PARP Inhibitors in Women's Cancers

Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based

Activity Overview

The advent of PARP inhibitor therapy is transforming the treatment landscape for your patients with breast and ovarian cancers. Because of the frequent and unique opportunities that you have to improve clinical outcomes for your patients, we have developed an engaging multimedia educational activity to enhance your understanding of the effectiveness of these new strategies, methods to mitigate and manage predictable and distinct adverse events, and the importance of counseling your patients concerning the use of these novel approaches, which are very different from traditional oncology agents in several aspects, including the way that they work and the efficacy and safety profiles that they carry.

This activity, featuring video commentary from a multidisciplinary panel of clinical experts, will present best practices that you can utilize in the treatment, management, and overall care of patients with breast and ovarian cancers who may be candidates for PARP inhibitor therapy. The latest clinical evidence will be discussed, as well as practical considerations to help you optimize patient management.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward all attendees of the ONS 43rd Annual Congress, including nurses and other healthcare professionals with an interest in the treatment of patients with breast and ovarian cancers.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Outline the underlying mechanisms by which PARP inhibitors exert their activity in the treatment of cancer
  2. Delineate key concepts and findings from pivotal trials that have evaluated PARP inhibitors for the treatment of ovarian and breast cancers
  3. Practically apply knowledge of PARP inhibitor strategies to real-world clinical scenarios in which nurses counsel patients with ovarian and breast cancers
  4. Develop processes to proactively mitigate the impact of adverse events in the treatment of ovarian and breast cancers


Lorraine Lopez, RN, BSN
Nurse Manager
Arizona Oncology – Biltmore Cancer Center
Division of Gynecology Oncology
Phoenix, AZ

Disclosures: No relevant financial relationships with commercial interests to disclose.

Bradley J. Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph’s Hospital
Phoenix, AZ

Disclosure: Consultant: Abbvie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Genmab, Gradalis, ImmunoGen, Incyte, Insys, Mateon, Merck, Myriad, Perthera, Pfizer, Precision Oncology, Roche/Genentech, Tesaro Inc, VBL Therapeutics; Speakers Bureau: AstraZeneca, Clovis, Janssen/ Johnson & Johnson, Roche/Genentech, Tesaro Inc.


Jennifer K. Litton, MD
Associate Professor
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant Research Support: AstraZeneca, Pfizer, EMD Serono, GlaxoSmithKline, Genentech; Consultant: AstraZeneca, Pfizer

Jill Schwartz-Gomez, RN, CCRP
Senior Research Nurse
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: No relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By